Abstract library

15 results for "T-cells".
#2284 The Association between Gastrin and Glucose Serum Concentration in Hypergastrinemic Patients with Gastric Neuroendocrine Tumors Type 1 and ECL-Cells Hyperplasia
Introduction: There is previous data demonstrating that elevated gastrin levels could exert some effect potentiating the glucose-induced insulin secretion.
Conference: 15th Annual ENETS conference (2018)
Category: Biomarkers
Presenting Author: MD Krystallenia Alexandraki
#1448 Distribution of T-Cell Infiltrate in G1, G2 and G3 NENs
Introduction: The identification of T-cell infiltrate and the expression of inhibitory molecules in the tumor microenvironment could lend support to the use of immunotherapy in the treatment of gastroenteropancreatic neuroendocrine neoplasms (GEP-NENs).
Conference: 13th Annual ENETS conference (2016)
Category: Pathology, grading, staging
Presenting Author: MD, PhD Massimo Milione
Keywords: Ki-67, T-cells, NEN
#1057 Localisation of Insulinoma and Beta-Cells: Comparison of Glucagon-Like Peptide-1 Receptor (GLP1-R) SPECT/CT, PET/CT and MRI. Preliminary Results of a Prospective Clinical Study.
Introduction: SPECT/CT imaging with GLP1-R specific radiotracers like 111In-DOTA-exendin-4 have already proved to be a useful tool for the preoperative localisation of insulinomas. PET/CT has several advantages over SPECT/CT: lower radiation exposure, less time consumption and higher spatial resolution.
Conference: 12th Annual ENETS Conference (2015)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dr. Christof Rottenburger
Authors: Rottenburger C, Antwi K, Heye T, Fani M, ...
#488 CUX1 Mediates Progression of Neuroendocrine Tumors
Introduction: CUX1 is a key mediator of tumor progression in pancreatic ductal adenocarcinoma (PDAC) and is upregulated during tumorigenesis in PDAC. It contributes to tumor invasion and is resistant to apoptosis and angiogenesis.
Conference: 9th Annual ENETS Conference (2012)
Category: Basic
Presenting Author: Dr. med. Sebastian Krug
Keywords: CUX1, angiogenesis
#788 A Novel Animal Model for Medullary Thyroid Carcinoma
Introduction: Medullary thyroid carcinoma (MTC) is a neuroendocrine cancer originating from calcitonin-producing C-cells. Surgical resection is the most effective treatment currently available. Understanding the molecular pathways mediating MTC is crucial for the development of novel therapies. Cyclin-dependent kinase 5 (Cdk5) and its activators, p35 and p25, have recently been implicated in MTC etiology. P25 is a cleavage product of p35 and the binding of p25 to Cdk5 leads to aberrant Cdk5 activity.
Conference: 10th Annual ENETS Conference (2013)
Category: Epidemiology/Natural history/Prognosis - Registries, nationwide and regional surveys
Presenting Author: Dr Karine Pozo
Authors: Pozo K, Castro-Rivera E, Tan C, Siegl V, ...
Keywords: thyroid, Cdk5
#1219 Changes in Neuroendocrine Tumor Microenvironment with WHO Tumor Grading
Introduction: The microenvironment of neuroendocrine neoplasias (NEN) in view of tumor grading (WHO classification of 2000 und 2010) has not yet been validated. Both classifications distinguish between well and poorly differentiated neuroendocrine tumors, including proliferation rate, mitotic index and histomorphology. The WHO classification of 2000 further evaluates tumor location, size, angioinvasion, invasion of the muscle layer, functionally active tumors and metastases.
Conference: 12th Annual ENETS Conference (2015)
Category: Biomarkers
Presenting Author: Dr. med. Silke Cameron
Authors: Cameron S, Skupin J, Füzesi L, ...
Keywords: NEN stroma
#18 Long-acting release octreotide induce complete response in type 1 gastric carcinoid tumors
Introduction: Gastric endocrine tumors (GET) are increasingly recognized due to expanding indications of upper gastrointestinal endoscopy. Often silent and benign, GET may also be aggressive when sporadic and may sometimes mimic the course of gastric adenocarcinoma. Current incidence of GETs is estimated at around 8% of digestive endocrine tumors. Yearly age-adjusted incidence is around 0.2 per population of 100,000. Gastric carcinoids (ECLomas) develop from gastric enterochromaffin-like cells (ECL cells) in response to chronically elevated gastrin. Type 1 tumors (ECLomas in the course of atrophic gastritis) may occur in conditions of achlorhydria secondary to auto-immune atrophic fundic gastritis. It occurs mostly in women and they are non-functioning tumors, typically found during upper GI endoscopy performed for dyspepsia. ECLomas present frequently as multiple polyps, usually < 1 cm in diameter in the gastric fundus. Type 1 tumors are almost exclusively benign lesions with little risk of deep invasion of the gastric parietal wall. The neoplastic ECL cells become progressively dedifferentiated with an increasing number of Ki-67 immunoreactive (IR) cell nuclei. In addition, there is a substantial decrease in argynophil and IR NE cells that can be visualized by conventional methods. ECLomas secondary to hypergastrinemia should be closely followed for signs of clinical and histopathological tumor progression. Such ECLomas deserve early, active, radical surgical treatment.
Traditionally, gastric carcinoid type 1 (GCA1s) are endoscopically or surgically removed, depending on the number, appearance and size of the tumors. Antrectomy, with surgical excision of the majority of the G cells, is thought to facilitate regression of these tumors by removing the source of excessive gastrin secretion; however, the long-term benefits of antrectomy still remain uncertain. Although proton pump inhibitors are effective in reducing hypergastrinemia-induced gastric acid hypersecretion in GCA2, they do not affect ECL-cell hyperplasia, and therefore their role in GCA1 is limited. Moreover, in selected cases, significant reduction of hypergastrinemia does not prevent development of ECL carcinoid, suggesting that, in addition to hypergastrinemia, other pathogenic or genetic factors may be involved. Treatment with somatostatin analogues (SSA) might impede ECL-cell hyperplasia by suppressing gastrin secretion and/or by a direct anti-proliferative effect on ECL cells. Treatment with SSAs in GCA1 leads to a substantial tumor load reduction, with a concomitant decrease of serum gastrin levels. Published data indicate an important anti-proliferative effect of SSA on ECL cells, providing clinical benefit and obviating, at least temporarily, the need for invasive therapies for GCA1. Morphometric studies demonstrated that, while antrectomy specifically decreased the volume of ECL cells versus the total volume of endocrine cells, octreotide reduces the overall endocrine cell volume. Although the number of treated patients is small, it has been suggested that SSA may exert important anti-proliferative effects either directly, by inhibiting ECL-cells proliferation, or indirectly through suppression of gastrin hypersecretion.
Conference: 7th Annual ENETS Conference (2010)
Category: Clinical
Presenting Author: MD Ricardo Caponero
#463 Primary Neuroendocrine Tumor of the Parathyroid
Introduction: Parathyroids are derived from third and fourth branchial pouches and neuroendocrine C-cells originate for neighboring fifth branchial pouch. A close ontogenic relation between these embryonal pouches is illustrated in DiGeorge syndrome wherein there is an absence of parathyroid glands and C-cells. It is not known for certain if normal parathyroids contain NE cells. However, NETs of the parathyroid have been reported in two other cases (Medline search: 1966-2011).
Conference: 9th Annual ENETS Conference (2012)
Category: Clinical
Presenting Author: Dr. Mohammed Ahmed
Authors: Ahmed M, ...
Keywords: parathyroid NET
#1182 Epirubicin Loaded Polyphosphazene; A New Agent Against Small Intestinal Neuroendocrine Tumors and Medullary Thyroid Carcinomas
Introduction: Small intestinal neuroendocrine tumors (SI-NETs) represent a group of rare neoplasms, derived mainly from enterochromaffine cells. Medullary thyroid carcinoma (MTC) is a calcitonin-producing neuroendocrine tumor arising from the parafollicular C-cells. SI-NETs as well as MTCs are known for their poor response to standard therapy. Therefore, there is a substantial need to establish new therapeutic options in the clinical treatment of these tumors.
Conference: 12th Annual ENETS Conference (2015)
Category: ...none of the below
Presenting Author: Dr. Gert Schwach
#1299 Clinical Value of Somatostatin Receptor Scintigraphy in the Management of Medullary Thyroid Carcinoma
Introduction: Medullary Thyroid Carcinoma (MTC) is a rare form of thyroid cancer. It represents 5 to 10 % of these cancers. MTC grows from specialized thyroid cells called para-follicular cells, or C-cells that secrete a hormone called calcitonin. Its prognosis is usually good. Recurrences can occur, requiring lifelong surveillance.
Conference: 13th Annual ENETS conference (2016)
Category: Imaging (radiology, nuclear medicine, endoscopy)
Presenting Author: Dorra Ben Sellem
Close
Notice

WARNING – FRAUDULENT WEBSITES

ENETS is aware that its members have been confronted with fake websites, which seem to relate to our congress but have not been commissioned or authorised by us. The websites offer fraudulent hotel reservation services. We therefore strongly recommend that you please only use the official enetsconference.org website when booking your tickets and accommodation. Please be vigilant when it comes to providing your credit card details. 

If you have any questions, please do not hesitate to contact us at info@enets.org.